Farmas USA

MNKD
Estaba subiendo un 8% en pre, y ya le están cascando un -15%. Todavía queda trecho hasta el $, por si alguien se atreve a meterle un corto.

Actualizado al 30.9.15 First Trust Advisors, NVAX en la posi 100 de la que largaron 3.731.885 cromos.
http://j3sg.com/Reports/Stock-Insider/Generate-Institution-Portfolio.php?institutionid=4650&DV=yes

MNKD

Bueno, como comentaba en el otro foro, yo me he animado esta tarde, y me he metido en 1.85.. de momento, la cosa va bien...

apenas 1,3 millones de cromos en NVAX , muy poco volumen, pero ahi andamos de nuevo tocando la moral al personal ...

NVAX

Mas vale que lo que este haciendo el IBB sea consolidar la zona de los 325-330 antes de dar el salto rally navideño 

NVAX
Temporada blood sweat&tears, pero llegarán tiempos mejores, sin duda:)

ARNA

Otra info extraída de la rueda de prensa:

we continue to support Eisai's efforts in their active dialogue with the health authorities in Mexico and Brazil as well as Teva in Israel.

Regarding Taiwan, CY Biotech recently filed an application for the approval of BELVIQ with their health authority.

In Europe, Eisai and Arena have met with EU health authorities regarding the resubmission of BELVIQ MA and we are discussing the results of this meeting to how best to proceed. We no longer expect Eisai to make a resubmission by the end of March 2016 as previously anticipated and do not have a specific date as to when a potential MAA re-filing could occur.

Eisai expects slow growth for the obesity market in general and for BELVIQ to continue to grow slowly until the results of the cardiovascular outcome study or CVOT are known and if positive incorporated into the product label. Proof of reduced risk of hospitalization during cardiovascular event would allow BELVIQ to be differentiated from competing products. demonstrating a decrease risk of hospitalization in major cardiovascular event would enhance BELVIQ insurance coverage. result of the CVOT study is not expected until 2018

PD371, a highly selected and potent cannabinoid 2 receptor agonist and development for the treatment of pain, we recently announced start of our Phase 1 multiple ascending dose study. Top line results for this study are expected in the first quarter of 2016.

collaboration with Roivant Sciences for nelotanserin, inverse agonist of the serotonin 2A receptor. Axovant is responsible for all development cost and has announced that it intent to initiative two Phase 2 clinical trials with nelotanserin in the first quarter of 2016. The first trial was planned in patients with either dementia with Lewy bodies, or Parkinson's disease dementia in patients who suffer from visual hallucinations. The second trial is planned in patients with dementia with Lewy bodies who are experiencing REM Behavior Disorder.

we expect to incur charges primarily in the fourth quarter of 2015 of approximately $3.3 million in connection with one time employee termination cost.

a estos precios me vuelvo a comprar unos cuantos cromos el dia de Nochebuena ...

ARNA

edito: o no :)

Ana, ¿y tu como ves ARNA? No estaría mal que Eisai nos hiciera un BO... como le ha pasado a OCAT.... ehhhh... jejejejeje...